OpenEvidence valued at $15B as studies probe its clinical performance
What happened
On October 21, Ars Technica reported that ad-supported AI startup OpenEvidence is valued at $15 billion and that doctors have adopted its software on their own. A study by investor Mayo Clinic found the software gave accurate, evidence-based advice in all five sampled patient cases, but had limited effect on treatment decisions. Other studies, including a paper in Nature in June, found OpenEvidence trailed general models such as Google Gemini and OpenAI GPT on clinical benchmarks. The report covers doctor adoption and how the studies differ on advice accuracy, decision impact and benchmark performance.
Written by AI from the coverage · updated 2 hours ago
Coverage
Follow the reports to see the story from different sides.
- Ars Technica · AIThe $15 billion ad-powered AI startup your doctor may already be using
OpenEvidence 是一家估值 $15 billion、由广告支持的 AI 初创公司，已有医生主动采用其软件。投资方梅奥诊所的研究发现，它在抽样的 5 个患者病例中均给出准确、基于证据的建议，但对治疗决策的影响较有限；包括 6 月 Nature 论文在内的其他研究发现，它在临床基准上落后于 Google 的 Gemini 和 OpenAI 的 GPT 等通用模型。
Heat over time
Not enough continuous observations to draw a trend yet.